Volume | 185,042 |
|
|||||
News | (2) | ||||||
Day High | 0.7662 | Low High |
|||||
Day Low | 0.7481 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
AlloVir Inc | ALVR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.7631 | 0.7481 | 0.7662 | 0.7525 | 0.7722 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,019 | 185,042 | $ 0.7549877 | $ 139,704 | - | 0.58 - 6.12 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:52:05 | 1 | $ 0.7728 | USD |
AlloVir Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
85.55M | 114.06M | - | 0 | -190.42M | -1.67 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
AlloVir News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALVR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.7402 | 0.7939 | 0.7402 | 0.7653948 | 252,025 | 0.0123 | 1.66% |
1 Month | 0.8199 | 0.8199 | 0.58 | 0.7570418 | 344,027 | -0.0674 | -8.22% |
3 Months | 0.6904 | 0.85 | 0.58 | 0.7673896 | 432,289 | 0.0621 | 8.99% |
6 Months | 2.29 | 2.485 | 0.58 | 0.8164908 | 1,266,726 | -1.54 | -67.14% |
1 Year | 5.76 | 6.12 | 0.58 | 1.57 | 1,068,541 | -5.01 | -86.94% |
3 Years | 23.05 | 26.41 | 0.58 | 4.64 | 676,588 | -22.30 | -96.74% |
5 Years | 22.82 | 48.96 | 0.58 | 7.80 | 599,290 | -22.07 | -96.70% |
AlloVir Description
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. |